On July 5, 2022, Shenzhen Kangtai Biological Products Co., Ltd.'s vaccine production base in Guangming District, Shenzhen received a GMP compliance declaration issued by the Philippine Food and Drug Administration (FDA), which means that all products produced at the Kangtai Guangming base All meet the requirements of the Philippine FDA, and it is expected to accelerate the registration and enter the local market in the future.
In May of this year, the Kangtai Bio-Adenovirus Vector COVID-19 Vaccine Production Base obtained a Declaration of Conformity issued by an EU Quality Authorized Person (QP). Kangtai biological production bases have successively passed overseas certification, indicating that the company's quality management system has reached international standards.
In the future, the company will continue to actively explore international market cooperation and sales channels, strengthen the overseas registration of products, explore diversified sales channels for products, and promote the realization of the internationalization strategy.
China, Malaysia companies inks deal on clinical trial, commercialization of COVID-19 vaccines
COVID-19: A Basic Guide to Different Vaccine Types and How They Work
With global push for COVID-19 vaccines, China aims to win friends and cut deals